This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Starting Treatment With Agonist Replacement Therapies Follow-up Study

This study has been completed.
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yih-Ing Hser, University of California, Los Angeles Identifier:
First received: May 3, 2012
Last updated: August 4, 2016
Last verified: August 2016

The purpose of the study is to conduct a follow-up of substance abuse patients (n=1,269) about 2 to 5 years since they were originally recruited from 8 substance abuse treatment clinics (located in 5 states) to participate in a prior clinical trial study called "START" (Starting Treatment with Agonist Replacement Therapies). The START Follow-up Study will be conducted over 5 years and will involve three follow-up interviews with START participants.

The specific aims of the START Follow-up Study are as follows.

  1. To determine longer-term outcomes of Suboxone versus methadone treatment received in the START
  2. To investigate patient and treatment factors associated with post-START treatment access, utilization, and outcomes among Suboxone and methadone patients
  3. To explore other correlates of the long-term outcomes among START patients.

Opioid Dependence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: START Follow-up Study (NIDA CTN Protocol 0050)

Further study details as provided by Yih-Ing Hser, University of California, Los Angeles:

Primary Outcome Measures:
  • Opioid use as determined by the Timeline Follow Back measure [ Time Frame: from 2006-2009 to 2011-2016 ]
    Opiate use over approximately ten years time period

Secondary Outcome Measures:
  • mortality [ Time Frame: from 2006-2009 to 2011-2016 ]
    Rate of mortality over approximately ten years time period

Enrollment: 877
Study Start Date: September 2010
Study Completion Date: August 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Participants will include the 1,269 study participants from the original START Study (CTN-0027) that was conducted from 2006 to 2010 at eight community treatment programs (CTPs).

Inclusion Criteria:

  • To be eligible to participate in the study, individuals must have participated in CTN-0027 START.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01592461

United States, California
Matrix Institute on Addictions
Los Angeles, California, United States, 90016
Bi-Valley Medical Clinic, Inc.
Sacramento, California, United States, 95838
BAART Programs
San Francisco, California, United States, 94102
United States, Connecticut
Hartford Dispensary
Hartford, Connecticut, United States, 06120
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
United States, Oregon
CODA, Inc.
Portland, Oregon, United States, 97214
United States, Pennsylvania
NET Steps
Philadelphia, Pennsylvania, United States, 19137
United States, Washington
Evergreen Treatment Services
Seattle, Washington, United States, 98134
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Principal Investigator: Yih-Ing Hser, Ph.D. University of California, Los Angeles
  More Information

Responsible Party: Yih-Ing Hser, Professor, University of California, Los Angeles Identifier: NCT01592461     History of Changes
Other Study ID Numbers: CTN-0050
U10DA013045 ( U.S. NIH Grant/Contract )
Study First Received: May 3, 2012
Last Updated: August 4, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Deidentified data will be shared via NIDA Clinical Trials Network Website

Keywords provided by Yih-Ing Hser, University of California, Los Angeles:
Substance abuse treatment outcomes
Opioid dependence
Methadone processed this record on September 21, 2017